氯吡格雷联合前列地尔治疗急性脑梗死的临床疗效分析

Clinical Efficacy of Clopidogrel Combined with Alprostadil in the Treatment of Acute Cerebral Infarction

目的观察氯吡格雷联合前列地尔治疗急性脑梗死的临床效果,评价其安全性。方法方便选取2016年1月—2017年4月在该院确诊并接受治疗的70例急性脑梗死患者,按照随机数字表法分为对照组(30例)与观察组(40例),对照组采用氯吡格雷单一治疗方式,观察在对照组治疗方案基础上联合前列地尔,比较两组患者治疗效果与不良反应发生情况。结果观察组临床治疗有效率为95.0%,显著高于对照组73.3%(P<0.05);两组患者不良反应发生率经比较,差异无统计学意义(χ~2=0.106,P>0.05);观察组患者的平均住院时间为(21.04±1.14)d,明显短于对照组(28.76±8.71)d,差异有统计学意义(t=4.814,P=0.000<0.05);观察组患者C反应蛋白(2.88±1.22)㎎/L、白细胞介素6(44.0±1.22)pg/mL、肿瘤坏死因子-(1.81±0.12)ng/mL、血小板采集率(40.13±11.37)%、组织纤溶酶原激活物(0.96±0.16),与对照组(3.42±2.05)㎎/L、(60.1±15.0)pg/mL、(2.12±0.22)ng/mL、(57.36±9.10)%、(0.42±0.11)、(1.06±0.18),除组织纤溶酶原激活物抑制物差异不显著外,其他实验室指标经比较,差异有统计学意义(t=4.264、9.854、5.247、6.754、4.587,P<0.05);但两组病例组织纤溶酶原激活物抑制物经比较,差异无统计学意义(P>0.05)。结论氯吡格雷联合前列地尔治疗急性脑梗死疗效显著,过程相对安全可靠,促进出院,具有借鉴价值。

Objective This paper tries to observe the clinical effect of clopidogrel combined with alprostadil in the treatment of acute cerebral infarction and evaluate its safety. Methods 70 patients with acute cerebral infarction diagnosed and treated in the hospital from January 2016 to April 2017 were convenient selected and randomly divided into the control group（30 cases） and the observation group（40 cases）. A single treatment with clopidogrel was used to observe the combination of alprostadil on the basis of the treatment regimen in the control group, and the treatment effects and adverse reactions were compared between the two groups. Results The effective rate of clinical treatment in the observation group was 95.0%,which was significantly higher than that in the control group（73.3%）（P〈0.05）; the incidence of adverse reactions in the two groups was not significantly different（χ^2=0.106, P〉0.05）; The average length of stay of patients was（21.04±1.14） d, which was significantly shorter than that of the control group（28.76 ±8.71） days. The difference was statistically significant（t=4.814, P=0.0000.05）. The patients in the observation group were C-reactive protein（2.88±1.22） mg/L, interleukin 6（44.0±1.22） pg/mL, tumor necrosis factor-（1.81±0.12） ng/mL, platelet collection rate（40.13±11.37） %, tissue plasminogen activator（0.96±0.16）, and control group（3.42±2.05） mg/L,（60.1±15.0） pg/mL,（2.12±0.22） ng/mL,（57.36±9.10） %,（0.42±0.11）,（1.06±0.18）, except that the tissue plasminogen activator inhibitors showed no significant difference, other laboratory indicators were statistically significant（t=4.264, 9.854, 5.247, 6.754, 4.587,P〈0.05）; but there was no significant difference in tissue plasminogen activator inhibitors between the two groups（P〉0.05）. Conclusion Clopidogrel combined with alprostadil is effective in the treatment of acute cerebral infarction, and the process is relatively safe and reliable. It promotes discharge and has reference value.